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Genome-wide association studies (GWASs) have identified many genetic variants underlying complex traits. Many detected genetic loci
harbor variants that associate with multiple—even distinct—traits. Most current analysis approaches focus on single traits, even though
the final results from multiple traits are evaluated together. Such approaches miss the opportunity to systemically integrate the phe-
nome-wide data available for genetic association analysis. In this study, we propose a general approach that can integrate association
evidence from summary statistics of multiple traits, either correlated, independent, continuous, or binary traits, which might come
from the same or different studies. We allow for trait heterogeneity effects. Population structure and cryptic relatedness can also be
controlled. Our simulations suggest that the proposed method has improved statistical power over single-trait analysis in most of the
cases we studied. We applied our method to the Continental Origins and Genetic Epidemiology Network (COGENT) African ancestry
samples for three blood pressure traits and identified four loci (CHIC2, HOXA-EVX1, IGFBP1/IGFBP3, and CDH17; p < 5.0 3 108) asso-
ciated with hypertension-related traits that weremissed by a single-trait analysis in the original report. Six additional loci with suggestive
association evidence (p < 5.0 3 107) were also observed, including CACNA1D andWNT3. Our study strongly suggests that analyzing
multiple phenotypes can improve statistical power and that such analysis can be executed with the summary statistics fromGWASs. Our
method also provides a way to study a cross phenotype (CP) association by using summary statistics from GWASs of multiple pheno-
types.Introduction
Genome-wide association studies (GWASs) have been a
major design to discover the genetic determinants of com-
plex traits, with thousands of common genetic variants
thus uncovered. The identification of genetic variants
reveals important biological insights into the genetic
architecture of complex traits such as hypertension (MIM
145500), human height (MIM 606255), and blood
lipids.1–3 It is well known that the effect sizes of identified
common variants are often small and that a large sample
size is necessary to ensure sufficient power to detect such
variants. A common strategy is to perform a meta-analysis,
combining the effect and variance estimates from as many
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The Aphenotypes, which does not require one to pool the indi-
vidual-level data, thereby reducing the logistical and
regulatory burden associated with transferring individual
data across centers,4 as well as avoiding the need to explic-
itly model study design differences or manage confound-
ing by genotyping batch effects and trait ascertainment
that differentially affect allele frequency estimates across
studies. Notably, GWASs are generally performed with
single traits (at a univariate level), although multiple
related phenotypes are often collected and studied and
are expected to reflect common physiological processes.
For example, a hypertension study often measures sys-
tolic blood pressure (SBP), diastolic blood pressure
(DBP), and hypertension status (HTN), and these pheno-
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that univariate analysis could suffer low statistical power
compared with multivariate analysis.4 Systematic simulta-
neous analysis of multiple traits could improve the quality
of inferences from analysis of outcomes that all relate to
the biological construct of interest.
The joint analysis of multiple phenotypes within a
cohort has recently become popular for improving statisti-
cal power to detect genetic linkage and association. Solo-
vieff et al. provided a detailed summary of such kinds of
approaches.4 Most multivariate methods are based on a
multivariate regression framework and require both geno-
types and phenotypes at the individual level, with an
assumption of approximately normally distributed pheno-
types. Extensions to allow for nonnormally distributed
phenotypes and categorical phenotypes have also been
developed based on generalized estimating equations
(GEEs), ordinal regression, and a Bayesian framework.6–10
On the other hand, approaches have been developed based
on a dimension reduction technique on the phenotypes,
such as principal-components (PCs) analysis and canoni-
cal correlation analysis.11,12 However, it has been reported
that testing only the top PCs has lower power than the
combined-PC approach.13
In contrast to multivariate analysis, a method for inte-
grating the results from standard univariate analyses
across various phenotypes in GWASs has recently been
developed. The Fisher’s combined p value method can
be applied to independent studies but is not straightfor-
ward when aggregating p values of different but correlated
phenotypes within the same cohort, which will result in
inflated type I error. The cross-phenotype meta-analysis
(CPMA) was developed for testing whether there is associ-
ation of a SNP to multiple phenotypes, rather than
directly evaluating the aggregated association evidence
between a SNP and multiple phenotypes.14 Although
the method can be applied to multiple independent
studies, it does not allow overlapping or correlated sam-
ples among studies. Standard fixed and random effects
meta-analysis methods are also used to combine associa-
tion across multiple phenotypes but are not well suited
to situations where a genetic variant has opposite effects
on different phenotypes. As an example, psoriasis (MIM
309480) and Crohn disease (CD) have been reported to
be positively correlated, with the prevalence of CD in in-
dividuals with psoriasis significantly higher than in con-
trols.15 However, the G allele of SNP rs12720356 in
TYK2 (MIM 176941) increases risk for Crohn disease
and decreases risk for psoriasis.16,17 For HTN-related traits,
SBP rises linearly with age, in the absence of treatment,
whereas DBP has an inverted ‘‘U’’ pattern with a zenith
around age 50. Although SBP and DBP are positively
correlated, a genetic variant might have opposite effect
for the two traits. An extension of fixed effects meta-anal-
ysis is the subset-based meta-analysis,18 which allows
opposite effects and is able to test association to a subset
of phenotypes. This method exhaustively searches all
possible phenotype subsets and identifies the subset of22 The American Journal of Human Genetics 96, 21–36, January 8, 20traits with the strongest association, but with the cost of
exponentially increased multiple tests. In addition, the
method does not allow for heterogeneity across cohorts
for the same phenotype. Several methods have also
been developed based on a linear combination of the
univariate test statistics.19,20 These methods have been
further used to test for association between correlated
traits and genetic markers.21,22 However, the authors
focus on only a single study with multiple traits measured
in the same individuals. In addition, individual-level ge-
notype and phenotype data are also required for the
method by Yang et al.22 The trait-based association test
that uses an extended simes (TATES) procedure combines
p values obtained in univariate analysis of traits measured
in the same individuals while correcting for correlations
among phenotypes.23 This approach can be challenging
when combining association evidence across multiple in-
dependent studies because the phenotype correlation ma-
trix can change from cohort to cohort. Another approach,
the pleiotropy regional identification method (PRIMe),24
evaluates pleiotropic loci in a genomic region with multi-
ple phenotypes based on results of GWASs. This method
calculates a pleiotropic index defined by the number of
traits with low association p values in a genomic region.
The flipping sign test uses p values obtained from individ-
ual trait analysis to combine association from multiple
correlated traits but requires computationally intensive
simulations to obtain combined p values at the genome-
wide significance level.5
In this study, we propose a general approach that can
integrate association evidence from multiple correlated
continuous and binary traits from one or multiple studies.
We allow for heterogeneity of effects for the same trait in
different studies that might result from different popula-
tions, environmental exposures, or designs. We also allow
heterogeneity effects for different phenotypes, which is
not unexpected in practice. In addition, population struc-
ture and cryptic relatedness can be controlled. For cryptic
relatedness, we also allow for overlapping or related sub-
jects between the different cohorts studied. Although the
proposed method is not specifically designed for identi-
fying subsets of associated traits, we will offer insight
into how to detect such subsets of traits.Material and Methods
Assume we have summary statistical results of GWASs from J
cohorts with K phenotypic traits. In each cohort, single SNP-trait
association was analyzed for each trait separately. Let Tijk be a sum-
mary statistic for the ith SNP, jth cohort, and kth trait. Let Ti ¼
(Ti11,...,TiJ1,...,Ti1K,...,TiJK)
T. For simplification, we omit the SNP in-
dex. Thus, T ¼ (T11,...,TJ1,...,T1K,...,TJK)T represents a vector of test
statistics for testing the association of a SNP with K traits. Let b ¼
(b11,..., bJ1,..., b1K,..., bJK)
T be the effect sizes of the SNP. The null
hypothesis is H0: b ¼ 0 and the alternative hypothesis H1 is that
at least one of the elements of b is not equal to zero. We use a
Wald test statistic Tjk ¼ ðbbjk=bsjkÞ, where bbjk and bsjk are the15
estimated coefficient and corresponding standard error for the kth
trait in the jth cohort. It is reasonable to assume that T follows a
multivariate normal distribution with mean 0 and correlation ma-
trix R under the null hypothesis. In practice, R needs to be esti-
mated and we will address that later. A standard method to test
b ¼ 0 is the test statistic SJK ¼ TTR1T, which has asymptotically
a c2 distribution with J 3 K degrees of freedom. This test is
omnibus with respect to the alternative hypothesis. When hetero-
geneous effects exist, in particular if a variant contributes to only a
subset of traits, this test is less powerful because of the large num-
ber of degrees of freedom. When the effect is homogeneous, i.e.,
the effect sizes are all the same regardless of traits or cohorts, the
most powerful test statistic is
SHom ¼
eTðRWÞ1T

eTðRWÞ1T
T
eTðWRWÞ1e ; (Equation 1)
which follows a c2 distribution with one degree of freedom, where
eT¼ (1,...,1) has length J3 K andW is a diagonal matrix of weights
for the individual test statistics.19,20 When the statistics in T are
mutually independent and W is diagonal with inverses of vari-
ances as elements, SHom is equivalent to an inverse variance
weighted meta-analysis. A similar method to SHom has previously
been proposed but it is not specifically for combining the effects
across multiple traits.24 Equivalently, we can take the sample sizes
for the weights, i.e., wjk ¼ ﬃﬃﬃﬃnjp for the sample size nj of the jth
cohort. Here we assigned more weight to a large study because a
large study carries more information than a small study. The
advantage of using sample size over inverse variance is that then
we do not need to worry about the traits being on different scales,
because a variance is dependent on the scale of measurement. In
this study we take wjk ¼ ﬃﬃﬃﬃnjp .
The homogeneous effect size assumption is unlikely to be true,
especially when multiple phenotypes are analyzed together. We
introduce a test statistic based on SHom, which is more powerful
than SJK for homogenous data, because it has one degree of
freedom. Ideally, we would like to have a test statistic that includes
only the cohorts and traits with a true contribution to the associ-
ation of a genetic variant under the alternative hypothesis H1. The
truncated statistic methods for combining statistical evidence
have been suggested for such an analysis.25,26 We adopt a similar
idea here. For a given t > 0, we let T(t) be the subvector of T satis-
fying jTjkj > t. That is, only the statistics in the vector T with an
absolute value larger than t will be kept. Similarly, we let R(t) be
a submatrix of R representing the correlation matrix and W(t) to
be the diagonal submatrix ofW, corresponding to T(t). To further
allow for different effect directions of a variant for different traits
in different cohorts, we let wjk ¼ ﬃﬃﬃﬃnjp 3signðTjkÞ. Thus, the signed
weights will lead to adding evidence to the association, whether
or not the effects of a variant are in the same or different direc-
tions. Define
SðtÞ ¼
eTðRðtÞWðtÞÞ1TðtÞ

eTðRðtÞWðtÞÞ1TðtÞ
T
eTWðtÞ1RðtÞ1WðtÞ1e : (Equation 2)
When t is large, S(t) can be undefined if jTjkj% t for all j and k. In
this case we define S(t) ¼ 0. Our test statistic is then
SHet ¼max
t>0
SðtÞ: (Equation 3)
The asymptotic distribution of SHet does not follow a standard
distribution but can be evaluated by simulation (see the section
Evaluating the Distribution of SHet under the Null Hypothesis).The AWe can rank the statistics jTjkj for all j and k and evaluate S(t) at
these values to obtain maxt>0 SðtÞ. Because SHet gives more weight
to the large trait-cohort specific statistics, it can maintain statisti-
cal power when heterogeneity exists.
Estimation of the Correlation Matrix R among Test
Statistics
We assume that the traits are quantitative but we can apply the
same argument for qualitative traits. Let Y1 and Y2 be two trait
vectors and G1 and G2 be two genotype vectors. Without loss
of generality, we assume no covariates. If Y1 and Y2 come from
the same study cohort, G1 and G2 are the same. We assume that
linear regressions were applied to evaluate the association evi-
dence between Y1 and G1 and between Y2 and G2. That is, we
have Y1 ¼ G1 b1 þ ε1 and Y2 ¼ G2 b2 þ ε2, where ε1  Nð0; Is21Þ
and ε2  Nð0; Is22Þ. Assume least-squares estimates were obtained
and let T1 and T2 be the corresponding Wald test statistics
for testing b1 ¼ 0 and b2 ¼ 0, respectively. Then
T1 ¼ GT1Y1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GT1G1s
2
1
q
and T2 ¼ GT2Y2=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GT2G2s
2
2
q
. The correlation
between T1 and T2 is
corrðT1;T2Þ ¼ G
T
1 covðY1;Y2ÞG2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GT1G1s
2
1
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GT2G2s
2
2
q : (Equation 4)
If Y1 and Y2 are two traits from the same cohort, thenwe haveG1¼
G2 and cov(Y1,Y2) ¼ r12Is1s2, where r12 is the correlation between
trait 1 and trait 2. We then have
corrðT1;T2Þ ¼ r12: (Equation 5)
If Y1 and Y2 are from different cohorts, then a correlation can be
induced only by either overlapping samples or related subjects
in the two cohorts. In either case, Equation 5 can capture the cor-
relation. We note that Equation 5 does not depend on individual
genotypes but only on the correlation between the two traits.
Thus, corr(T1,T2) can be estimated from the summary statistics
for all the independent SNPs in a genome-wide association study.
That is,
corrðT1;T2Þ ¼
P
iðTi1  m1ÞðTi2  m2ÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
iðTi1  m1Þ2ðTi2  m2Þ2
q ; (Equation 6)
where T1,T2 are the test statistics for the SNP for traits 1 and 2 in
their corresponding cohorts, and m1 and m2 are their corresponding
means. We suggest using independent SNPs across the genome in
Equation 6 rather than all the SNPs regardless of the LD among
them, which will lead to inflated correlation estimation.27
Evaluating the Distribution of SHet under the Null
Hypothesis
Although SHom follows a c
2 distribution with one degree of
freedom, SHet does not have a closed form under the null hypoth-
esis because of the data-adaptive approach we are using. However,
SHet can be viewed as the maximum of weighted sum of trait-spe-
cific test statistics satisfying different thresholds, which is closely
related to a gamma distribution.28 We assume under the null hy-
pothesis that SHet follows a gamma distribution with a mean shift
and we use simulations to estimate this gamma distribution. Un-
der the null, a correlation between two test statistics T1,T2 is deter-
mined by the trait correlation in Equation 2 and is independent of
the SNP. Instead of generating genotype and phenotype data, we
can directly simulate the test statistic T from amultivariate normalmerican Journal of Human Genetics 96, 21–36, January 8, 2015 23
Table 1. Comparison of Trait Correlations Used for Simulation
and Estimated by Test Statistics from SNPs of GWASs
SBP DBP HTN
SBP – 0.76 0.73
DBP 0.69 – 0.70
HTN 0.66 0.60 –
Values above diagonal are generating correlation coefficients, and under diag-
onal are estimated based on the test statistics of 100,000 SNPs.distribution Nð0; bRÞ, where bR is the estimated correlation matrix
given by Equation 6. We use the following steps to evaluate the
distribution under the null hypothesis:
(1) Estimate the correlation matrix bR by Equation 6 with the
observed test statistics across the common genome-wide
SNPs for all cohorts and traits.
(2) Generate L random vectors from the multivariate normal
distribution Nð0; bRÞ.
(3) For the lth realization in step 2, calculate the test statistic
SHet,l as in Equation 3. The weight matrix in Equation 2 is
calculated with the cohort sample sizes.
(4) Fit SHet,1, SHet,2, ...SHet,L to a gamma distribution gamma(a, b)
þ c, where a, b are the shape and scale parameters and c is a
constant, and we estimate parameters a, b, and c by match-
ing the first three moments to the data. The estimated pa-
rameters are represented by ba, bb, and bc, respectively.
(5) For any observed statistic SHet,o, the p value is calculated
by p ¼ ProbðSHet;o  bc > S0Þ, where S0 is the fractile corre-
sponding a significance level a0 of the distribution
gammaðba; bbÞ.
The above procedure is not dependent on the particular SNP and
this null distribution gammaðba; bbÞ can be used for testing any SNP
association, which drastically reduces the computation time.
Notably, we can also directly use simulated SHet,1, SHet,2, ...SHet,L
as the distribution under the null hypothesis. However, the
computation is still intensive for GWASs because of the need to
evaluate test statistics at a significance level of 53 108. We there-
fore suggest the use of the estimated gamma distribution.Simulations
We conducted simulations to evaluate the type I error and power
of the proposed method. Five cohorts with 3,000 individuals each
and three blood pressure traits were generated. We allowed a
portion of the samples to overlap among the cohorts, which simu-
lated cryptic relatedness between samples from different cohorts.
The simulated data mimicked the blood pressure data from the
COGENT BP consortium,5 which included SBP, DBP, and HTN.
The correlations between SBP and DBP was obtained from the
CARe data. We first simulated a genotype gi for the i
th individual
with a minor allele frequency being sampled from a uniform dis-
tribution between 0.01 and 0.5, with the assumption of Hardy-
Weinberg equilibrium.
To simulate the phenotype data, we first generated latent phe-
notypes by using a linear additive model
Y 0i ¼ mþ bgi þ εi; (Equation 7)
where Y 0i , m, b, and εi are column vectors of length 2, representing
traits, intercepts, trait-specific effect sizes of a genotype, and24 The American Journal of Human Genetics 96, 21–36, January 8, 20random errors. We used parameters estimated from actual African
American data. In our simulation, we simulated Y 0i consisting of
SBP and DBP, with population means 127 and 78, respectively,
and εi  MVN

0;

s21 rs1s2
rs1s2 s
2
2

, where we let s21 ¼ 412,
s22 ¼ 132 and r is the correlation between SBP and DBP, which
we varied. To simulate HTN, we assumed that individuals with
either Y 0i1 > 140 or Y
0
i2 > 90 have antihypertensive medications.
The effects of antihypertensive medications for SBP and DBP fol-
lowed the normal distributionsNð10;s21=4Þ andNð5;s22=4Þ, respec-
tively. These effects of medications mimic the current GWASs for
which ten and five units are often added to SBP and DBP when
an individual is on antihypertensive medications.5,29 The
observed phenotype values for SBP and DBP are
Yi ¼ Y 0i  ε0i when the ith individual is on medication;
(Equation 8)
Yi ¼ Y 0i when the ith individual is not on any medication;
where ε0i  MVN

10
5

;

s21=4 0
0 s22=4

. The hypertensive case is
defined as either observed SBP > 140 (equivalently Yi1 > 140),
observed DBP > 90 (equivalently Yi2 > 90), or on antihyperten-
sive medication. Otherwise, a control is defined. The above simu-
lation process was used to generate the data under both the null
and alternative hypotheses for five cohorts. For data under the
null hypothesis, we simply let b¼ 0 in Equation 7. For data under
the alternative hypothesis, we set the phenotypic variance ex-
plained by a variant as 0.3% of total variance and calculated
the b value according to the simulated causal variant allele
frequency assuming an additive model of inheritance. In the
case of heterogeneity across cohorts, we set b with the calculated
value in one cohort and 0 in the rest of the cohorts.Results
We first examined whether the correlation among pheno-
types can be well estimated by the corresponding genome-
wide test statistics, as represented in Equations 5 and 6. We
simulated three correlated traits (SBP, DBP, and HTN) via
the method above but with genetic effects b ¼ 0 and r ¼
0.7 for 3,000 subjects. We also simulated 100,000 inde-
pendent SNPs for each individual with minor allele fre-
quencies being sampled from a uniform distribution
between 0.01 and 0.5, with the assumption of Hardy-
Weinberg equilibrium. We performed association tests for
all the SNPs with the software Plink.30 Table 1 shows the
estimated correlation among the three traits using trait
values and the estimated correlation matrix based on the
test statistics of 100,000 SNPs. We observed that the trait
correlations can be approximated through the calculation
of correlations of test statistics of SNPs corresponding to
traits (Table 1).
We next examined the type I error of statistics SHom and
SHet under three scenarios: (1) r ¼ 0, (2) r ¼ 0.25, and (3) r
¼ 0.5. For each scenario, we simulated 5 independent co-
horts each with 3,000 subjects, 100,000 SNPs, and three
traits (SBP, DBP, and HTN) under the null hypothesis of15
A B
C D
E F
Figure 1. SHet Distribution
Distribution of the test statistic SHet under
three scenarios: trait correlation is 0 (A
and B), trait correlation is 0.25 (C and D),
and trait correlation is 0.5 (E and F). We
generated 5 cohorts, each with sample
size 3,000, with no overlapping samples
between cohorts. Left panel is the histo-
gram of SHet based on 100,000 replications
and the red curve represents the theoret-
ical distribution gamma(a,b), where a,b
are the shape and scale parameters that
were estimated by matching the first two
moments. Right panel is a QQ plot of SHet.no genetic contribution to any of the three traits. We per-
formed the association tests for all the SNPs with the soft-
ware Plink30 to obtain the test statistics in each cohort
separately. We next calculated SHet for all the 100,000
SNPs and estimated the parameters a, b, and c for the
shifted gamma distribution by matching the first three
moments. Figure 1 depicts the empirical distributions of
SHet  bc under the three scenarios when no overlapping
subjects were generated between the five cohorts. We
observed that the estimated gammaðba; bbÞ fits the empirical
distribution of SHet  bc well (Figure 1). In particular, we
did not observe a departure in the tail of the gamma dis-
tribution. We observed similar results when there were
500 overlapping subjects among the five simulated co-
horts (Figure 2). We next used these estimated gamma dis-
tribution parameters to evaluate the type I error rates
correspondingly.
Under each of six scenarios (r ¼ (0, 0.25, 0.5) 3
(nonoverlapping, overlapping sample)), we repeated the
above process 100 times, which led to 107 SHom and SHetThe American Journal of Humstatistics. We calculated p values of
SHom statistics by c
2
1 and SHet statistics
by using the shift gamma distribu-
tion with previous estimated corre-
sponding parameters, respectively.
We then calculated the type I error
rates by evaluating the proportion
of the p values less than a signifi-
cance level. Table 2 presents the
type I error rates at different signifi-
cance levels. We observed that the
type I error rates were well controlled
for SHom. For SHet, type I error rates
were slightly inflated when signifi-
cance levels were less than 105.
Thus, the proposed SHet test statistics
can be fitted reasonably well by an
estimated shift gamma distribution
under the null hypothesis. Because
the distribution of SHet under the
null hypothesis depends only on the
correlation matrix among traits and
number of cohorts and does notdepend on a SNP, we can estimate the gamma (a, b) þ c
that canbe used for testing any SNP. Thismethod is compu-
tationally feasible. We also observed that the type I
error can be well controlled for SHom, which follows c
2
1
under the null hypothesis. The well-controlled type I
error rates for both SHom and SHet regardless of nonoverlap-
ping or overlapping samples among cohorts indicates
that correlations estimated by Equation 6 are well enough
for approximating the induced correlations among the
summary statistics by overlapped samples.
Power
We evaluated the power of the statistics SHom and SHet by
simulating three traits, SBP, DBP, and HTN. To simulate
the three traits, a SNP was simulated and its genetic effect
was added correspondingly. For illustration, we simulated
two scenarios: r ¼ 0 and r ¼ 0.5. In both scenarios, HTN
is always correlated with SBP and DBP because of the way
the data were simulated. In each scenario, we generated 5
cohorts, each with a sample size of 3,000 subjects. Wean Genetics 96, 21–36, January 8, 2015 25
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Figure 2. SHet Distribution when Cohorts
Have Overlapping Subjects
Distribution of the test statistic SHet under
three scenarios as in Figure 1. We gener-
ated 5 cohorts, each with sample size
3,000; 500 subjects were overlapping be-
tween cohorts. Left and right panels are
as in Figure 1.allowed different genetic contributions to the traits: a
genetic variant contributes to a trait in only one of five
cohorts (heterogeneity across cohorts within the same
trait) or in all five cohorts (no heterogeneity within a
trait), and a genetic variant affects SBP only (heterogene-
ity between traits) or affects both SBP and DBP. After
both genotypes and phenotypes were simulated, we
perform association tests for all SNPs with the software
Plink and calculated SHom and SHet. We calculated the p
values for SHom by a c
2
1 and with the previous estimated
shift gamma distribution for SHet, respectively. Power
was defined as the proportion of test statistics with p
values less than a corresponding significance level. We
also examined the power when there were 500 overlap-
ping subjects between cohorts. We analyzed the power
of SHom for SBP, DBP, and HTN, separately as well as
combined, and this is denoted as SHomSBP, SHomDBP,
SHomHT, and SHom, respectively. Power analysis was calcu-
lated based on 1,000 replications.26 The American Journal of Human Genetics 96, 21–36, January 8, 2015We first examined the power when
SBP and DBP were simulated inde-
pendently. Figure 3 shows the power
when a genetic variant contributes to
only one of the five cohorts, which
represents heterogeneity across co-
horts for the same trait. When a ge-
netic variant contributes only to
SBP, SHet has the best power, followed
by SHomSBP, SHom, and SHomHT
(Figure 3A). SHomDBP did not have
power because there was no genetic
contribution to DBP. This result sug-
gests that the proposed statistic SHet
is able to capture association evi-
dence even when the data include
noise because of heterogeneity
among traits and cohorts. SHomSBP
has more power than SHom, which is
not surprising because SHom included
DBP, which had no genetic contribu-
tion. The overlap of subjects across
the five cohorts is equivalent to
reducing the number of subjects
who did not have a genetic contribu-
tion from SBP. It is thus not surpris-
ing that SHomSBP had the most
power in this situation (Figure 3B).
When a genetic variant contributesto both SBP and DBP in one cohort with the effect sizes
in the same direction, the combined trait analyses by
SHom and SHet had much improved power although SHet
still had the greatest power (Figure 3C). The power for
SHom was further improved when there were overlapping
samples between studies (Figure 3D), which could be
attributed to reduced heterogeneity across cohorts.
When a genetic variant contributed to both SBP and
DBP in one cohort but with the effects in opposite direc-
tions, SHet still maintained power, whereas SHom had
almost no power because of the cancellation of the SBP
and DBP contributions whether or not there were overlap-
ping samples among cohorts (Figures 3E and 3F).
Figure 4 shows the power when a genetic variant con-
tributes to all five cohorts, which represents no heteroge-
neity across cohorts for the same trait. When a genetic
variant contributed only to SBP, SHomSBP had the most po-
wer, regardless of whether there were overlapping samples
or not between cohorts (Figures 4A and 4B). The power of
Table 2. Type I Error Rates for SHom and SHet
r
No. of Overlapped
Samples
Significance Level
0.05 102 103 104 105 106 107
SHom
0.00 0 5.03 3 102 9.99 3 103 9.96 3 104 9.74 3 105 1.00 3 105 8.00 3 107 3.00 3 107
500 4.76 3 102 9.18 3 103 9.02 3 104 9.05 3 105 6.50 3 106 8.00 3 107 2.00 3 107
0.25 0 5.04 3 102 1.02 3 102 1.03 3 103 1.07 3 104 1.12 3 105 7.00 3 107 0.00 3 100
500 4.94 3 102 9.81 3 103 9.52 3 104 9.57 3 105 9.50 3 106 7.00 3 107 1.00 3 107
0.50 0 5.06 3 102 1.02 3 102 1.03 3 103 1.06 3 104 1.23 3 105 1.10 3 106 0.00 3 100
500 4.74 3 102 9.21 3 103 8.65 3 104 7.97 3 105 7.30 3 106 7.00 3 107 2.00 3 107
SHet
0.00 0 4.99 3 102 1.00 3 102 1.03 3 103 1.10 3 104 1.17 3 105 2.00 3 106 1.00 3 107
500 4.99 3 102 1.00 3 102 1.01 3 103 1.06 3 104 1.30 3 105 1.70 3 106 1.00 3 107
0.25 0 4.98 3 102 9.98 3 103 1.04 3 103 1.11 3 104 1.25 3 105 1.10 3 106 2.00 3 107
500 4.98 3 102 1.00 3 102 1.02 3 103 1.11 3 104 1.28 3 105 8.00 3 107 0.00 3 100
0.50 0 4.99 3 102 1.01 3 102 1.05 3 103 1.10 3 104 1.23 3 105 1.30 3 106 1.00 3 107
500 4.99 3 102 1.01 3 102 1.05 3 103 1.15 3 104 1.26 3 105 1.30 3 106 2.00 3 107
Type I error rate was calculated from the asymptotic c2 distribution with 1 d.f. for SHom, and the shift gamma distribution parameters were estimated by matching
the first three moments for SHet. We simulated ten million replications for each scenario.SHom and SHet were comparable, with SHet outperforming
SHom for no overlapping samples between cohorts. When
a genetic variant contributed to both SBP and DBP and
the effects were in the same direction (no trait or cohort
heterogeneity), SHet performed similarly to SHom (Figures
4C and 4D). However, SHom had no power although SHet
maintained power when the genetic effects were in oppo-
site directions (Figures 4E and 4F).
The results were similar when SBP and DBP were highly
correlated (correlation coefficient ¼ 0.5). That is, SHet usu-
ally outperformed or performed equivalently well as the
other test statistics when heterogeneity due to cohorts
or traits were present in our simulated data (Figures 5
and 6). Interestingly, SHet improved power substantially
when a genetic variant contributed to SBP and DBP in
opposite directions but SBP and DBP were positively
correlated, compared with no correlation (Figures 3E and
3F versus Figures 5E and 5F). Intuitively, if two traits are
highly positively correlated, we are less likely to observe
the estimated effects for a variant in opposite directions
under the null hypothesis. The same is true if two traits
are highly negatively correlated, wherein we will less
likely observe the estimated effects for a variant in the
same directions under the null hypothesis. The test statis-
tic SHet apparently captures this information whereas SHom
does not.
Application to the BP GWAS Data from the
Continental Origins and Genetic Epidemiology
Network
We applied SHet and SHom to the BP data from COGENT
BP, which consists of 19 African ancestry cohorts, asThe Adetailed in Franceschini et al.5 In brief, the COGENT
study includes 29,378 subjects, 20 years or older, from
18 U.S. African American cohorts and one cohort from
Yoruba, Nigeria. The African American cohorts include
Biological bank of Vanderbilt University (BioVU), Athero-
sclerosis Risk In Communities (ARIC), Coronary Artery
Risk Development in Young Adults (CARDIA), Cleveland
Family Study (CFS), Jackson Heart Study (JHS), Multi-
Ethnic Study of Atherosclerosis (MESA), Cardiovascular
Health Study (CHS), Genetic Study of Atherosclerosis
Risk (GeneSTAR), Genetic Epidemiology Network of Arte-
riopathy (GENOA), Healthy Aging in Neighborhoods of
Diversity Across the Life Span Study (HANDLS), Health,
Aging, and Body Composition (Health ABC) Study, the
Hypertension Genetic Epidemiology Network (Hyper-
GEN), the Mount Sinai study (New York City, NY, USA),
the Women’s Health Initiative SNP Health Association
Resource (WHI-SHARe), the Howard University Family
Study (HUFS), the Bogalusa Heart Study (Bogalusa), the
Sea Islands Genetic NETwork (SIGNET) and REGARDs,
and the Loyola Maywood study (Maywood). Each study
received IRB approval of its consent procedures, examina-
tion and surveillance components, data security mea-
sures, and DNA collection and its use for genetic research.
All participants in each study gave written informed con-
sent for participation in the study and to conduct genetic
research. Genotyping for the 19 cohorts was performed
with either Affymetrix or the Illumina whole-genome
SNP genotyping arrays. Quality control of genotyping
data and imputation were performed in each cohort
separately. Uniform protocols for analysis were con-
ducted by each study. The summary statistics from themerican Journal of Human Genetics 96, 21–36, January 8, 2015 27
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Figure 3. Power Comparison of SHom and
SHetwhen One Cohort Has Genetic Contri-
bution
SBP and DBP were simulated indepen-
dently. HTN was simulated according to
SBP and DBP and simulated medication
status. Five cohorts were simulated, but
only one of the five cohorts has a genetic
contribution. Left: No overlapping sam-
ples among the five cohorts. Right: 500
samples were the same in each cohort
and a genetic variant contributes pheno-
typic variation for the same samples.
(A and B) A genetic variant affects only SBP.
(C and D) A genetic variant affects both
SBP and DBP but with opposite effect di-
rections.
(E and F) A genetic variant affects both SBP
and DBP with the same effect direction.GWASs, including the SNP estimated effect sizes and their
corresponding standard errors for SBP, DBP, and HTN,
were collected for meta-analysis.5 In this analysis, we
applied SHet and SHom to these summary statistics. Because
we observed many unexpected large estimated effect sizes
for the HTN analysis in SIGNET, we excluded the HTN re-
sults of SIGNET. Thus, our analysis included 56 trait-spe-
cific results from GWASs.
We obtained the inverse variance weighted meta-anal-
ysis results with the software METAL31 for SBP, DBP, and
HTN from the original report,5 where SNP rs11041530 at
CYB5R2 (MIM 608342) is the only variant reaching
genome-wide significance (SBP, p ¼ 4.0 3 108). We
calculated the proposed statistics SHet and SHom for each
SNP and the corresponding p values with a gamma distri-
bution for combining SBP, DBP, and HTN. Figure 7 pre-
sents the QQ plots and Manhattan plots of SHet and
SHom. The genomic control (GC) inflation factors are
1.08 and 1.05 for SHet and SHom, respectively. A possible28 The American Journal of Human Genetics 96, 21–36, January 8, 2015reason for the slightly inflated GC
factors could be that the hyperten-
sion traits are polygenic with a large
number of genetic variants of small
effect sizes contributing to the
phenotypic variation. Combining
SBP, DBP, and HTN would further
aggregate these variants. SHom de-
tected the HOXA-EVX1 (MIM
142996) locus on chromosome 7 at
a genome-wide significance level
(Table 3 and Figure 7, p ¼ 2.35 3
109). This locus was also reported
in the original study and was repli-
cated in Asian and European pop-
ulations, although SBP, DBP, or
HTN trait-specific meta-analyses did
not reach genome-wide significance
in the discovery phase.5 In compari-
son, SHet was able to detect fourloci at genome-wide significance level (p < 5.0 3
108), including HOXA-EVX1 on chromosome 7, CHIC2
(MIM 604332) on chromosome 4, IGFBP1-IGFBP3 (MIM
146730, 146732) on chromosome 7, and CDH17 (MIM
603017) on chromosome 8 (Table 3 and Figure 7). The
regional plots for these four loci are presented in Figure 8.
Figure S1 (available online) shows forest plots of the
cohort-specific effect sizes of SBP, DBP, and HTN for these
four loci. Note that these loci have opposite directions in
SBP and DBP meta-analysis except HOXA-EVX1 (Table 3),
suggesting that the same genetic variant increases SBP
but decreases DBP level (i.e., increases pulse pressure)
or vice versa. Interestingly, CHIC2 has been reported to
be associated with pulse pressure by large GWASs in a
European population.32 The most significant variant,
rs11725861 in CHIC2, is located 3 kb away from the
sentinel SNP rs871606 reported in Wain et al.,32 and
these two SNPs are in strong linkage disequilibrium in
HapMap CEU data (r2 ¼ 0.35, D’ ¼ 1). Because pulse
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Figure 4. Power Comparison of SHom and
SHet when Five Cohorts Have Genetic
Contribution
Five cohorts were simulated and the ge-
netic variant has contribution in all five
cohorts. Details as in Figure 3.pressure is defined as the difference between SBP and
DBP, the opposite effect sizes of SBP and DBP in this
study are thus consistent with the reported association
evidence with pulse pressure in European population.
The IGF system is implicated in the development of
cardiovascular disease. Low circulating levels of IGFBP1
have been reported to be associated with the presence
of macrovascular disease and hypertension in type 2
diabetes,33,34 although there is no direct report of associ-
ation evidence between the variants at IGFBP1 and
blood pressure. However, a recent meta-analysis of Euro-
pean cohorts identified IGFBP3 as being associated with
long-term averaging of pulse blood pressure.35 The
most significant variant, rs11977526 near IGFBP3, is
located 43 kb away from the sentinel SNP rs2949837
reported in Ganesh et al.35 and these two SNPs are
in strong linkage disequilibrium in HapMap CEU data
(r2 ¼ 0.66, D’ ¼ 0.94). There has been no association re-
ported between CDH17 on chromosome 8q21 and bloodThe American Journal of Humpressure, although linkage evidence
was reported for this locus to
essential hypertension in European
population.36
Six additional loci were also identi-
fied by SHet with suggestive evidence
(p < 5 3 107, Table 3). The muta-
tions in CACNA1D (MIM 114206),
encoding Cav1.3, were reported to
regulate Naþ, Kþ, and Ca2þ and to un-
derlie a common subtype of adrenal
hypertension.37 The SNP rs6886515
on chromosome 5 is located in an in-
tergenic region. SNP rs9401512 is in
HSF2/PKIB (MIM 140581, 606914)
on chromosome 6 and has not been
reported to be associated with hyper-
tension-related traits. However, this
region has been reported to harbor
BP variants in admixture mapping
analyses.38,39 SNP rs11041530 in
CYB5R2 was reported in the original
study but was not significant in a
replication analysis.5 We have not
seen any report of PLXNC1 (MIM
604259) and hypertension. SNP
rs430685 locates in WNT3 (MIM
165330) on chromosome 17 and this
locus is close to the locus GOSR2
(MIM 604027) reported in Ehretet al.1 SNP rs430685 is 153 kb away from the sentinel
SNP rs17608766 reported in Ehret et al.1 with D’ of 1.0
but r2 value of 0.003 between these two SNPs in HapMap
CEU data, indicating that these two signals might be
different. WNT3 belongs to the Wnt/frizzled receptor
signaling pathway, which has been suggested to have
an important functional role in cardiovascular and renal
disorders.40Discussion
The observations from GWASs suggest that many genetic
variants are associated with multiple correlated or even
distinct traits, and such associations have been termed
cross-phenotype (CP) associations,4 which is relevant to
pleiotropy in complex disease. We proposed a statistic
SHet and compared it with SHom, and both methods can
integrate association evidence of multiple continuousan Genetics 96, 21–36, January 8, 2015 29
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Figure 5. Power Comparison of SHom and
SHet with Correlation 0.5 when One
Cohort Has Genetic Contribution
SBP and DBP were simulated with correla-
tion 0.5. Five cohorts were simulated but
only one of the five cohorts has a genetic
contribution. Details as in Figure 3.and binary traits from multiple GWASs and thus detect
CP associations. Both methods need only the summary
statistics obtained from GWASs. SHom is an extension of
the linear combination of the univariate test statis-
tics19,20 but allows for sample size as weights. SHet is a
further extension of SHom allowing for heterogeneous ef-
fects of a trait from different studies, which could be due
to different designs, environmental factors, or popula-
tions, as well as heterogeneity effects for different pheno-
types, which are not unexpected in practice. Under the
null hypothesis, SHom is asymptotically distributed as
chi-square with 1 degree of freedom, although the
asymptotical distribution of SHet is less clear but related
to a gamma distribution.28 Our simulations indeed sug-
gest that SHet can be well approximated by a shift gamma
distribution with parameters that can be estimated from
the data.
The simulations indicated that the type I error rate is
reasonably controlled for both methods (Table 2 and Fig-30 The American Journal of Human Genetics 96, 21–36, January 8, 2015ures 1 and 2). The estimated gamma
distributions well fitted the corre-
sponding empirical distributions as
observed from both histograms and
the Q-Q plots of SHet (Figures 1 and
2). When we applied both methods
to the data from COGENT BP African
ancestry GWASs for blood pressure
traits, we did not observe any sub-
stantial inflation of the type I error
rate (Figure 7), further indicating
that both methods are valid.
Our simulations suggest that when
heterogeneity is of less concern, SHom
is more powerful than SHet. In
contrast, when heterogeneity is pre-
sent, SHet is more powerful than
SHom. This property can also be
observed from the application of
both statistics to the data from
COGENT BP African ancestry GWASs
for blood pressure traits. SHom was
able to detect the HOXA-EVX1 locus
(p ¼ 2.35 3 109) whereas SHet iden-
tified four loci (CHIC2, HOXA-EVX1,
IGFBP1/IGFBP3, and CDH17; p <
5.0 3 108) at a genome-wide signif-
icance level. All four loci were missed
by single-trait analysis at genome-
wide significance level (p < 5.0 3108) and only the HOXA-EVX1 locus was identified by
the flipping sign test in the original report,5 suggesting
that SHet is more powerful than combined p values
methods when heterogeneity is present. The flipping
sign test is similar to Fisher’s method for combining the
p values for different traits but requires a large number
of simulations to estimate the null distribution to account
for the trait correlations. Thus the flipping sign test is
similar to SHom but SHom is more flexible and requires sub-
stantially less computational time because of using the
estimated asymptotic distribution. The HTN-, SBP-, and
DBP-specific meta-analysis of the HOXA-EVX1 locus did
not show any heterogeneity (Table 3), which is the reason
that this locus was detected by SHom. As suggested by our
simulations, SHet is more applicable to heterogeneous data
and was able to identify three additional loci, CHIC2,
IGFBP1/IGFBP3, and CDH17. This is also consistent with
the fact that the effect sizes estimated in the SBP- and
DBP-specific meta-analyses were in opposite directions
A B
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Figure 6. Power Comparison of SHom and
SHet with Correlation 0.5 when Five Co-
horts Have Genetic Contribution
SBP and DBP were simulated with correla-
tion 0.5. Five cohorts were simulated and
the genetic variant has a contribution in
all five cohorts. Details as in Figure 3.for all three of these loci (Table 3). In addition, SHet
was able to identify six loci with suggestive association
evidence for hypertension-related traits. Among the
identified loci, CHIC2, HOXA-EVX1, IGFBP1/IGFBP3,
CACNA1D, and GOSR2/WNT3 have been confirmed to
be associated with hypertension-related traits,5,32–35 sug-
gesting that our methods powerfully identify true signals.
Compared with existing methods, SHom and SHet have
multiple advantages for identifying cross-phenotype
(CP) associations. Both methods are able to combine
traits measured on different scales, including continuous
and binary traits. Further, SHet allows for heterogeneous
effects. Both methods are able to accommodate overlap-
ping or related subjects within and among different
studies or cohorts, as our simulations suggested. We
assumed that the trait-specific summary statistics have
already well accounted for the confounding effect caused
by either population structure or cryptic relatedness
within a cohort. Since our approach accounts for correla-The American Journal of Humations of test statistics among traits or
cohorts, SHom and SHet are able to
control the effect of cryptic related-
ness occurring among cohorts, as
observed in the simulations when
overlapping samples were simulated
among cohorts (Figures 3, 4, 5, and
6). SHom and SHet are in principal
able to control the effect of popula-
tion structure occurring between co-
horts, although this property of the
methods has not been formally eval-
uated in our simulation studies.
In contrast, a fixed or random ef-
fect meta-analysis is able to combine
results from multiple studies but is
limited to the same traits and no
overlapping or related subjects across
studies. The cross-phenotype meta-
analysis14 is able to test CP associa-
tion but cannot be applied when
there are overlapping subjects. The
linear combination of univariate
test statistics applies only to a single
study with multiple traits and re-
quires individual-level genotype and
phenotype data.17,18 The TATES re-
quires only p values, not the individ-
ual-level genotype and phenotype
data, but cannot be applied to multi-ple studies.23 The scaled marginal model proposed by
Schifano et al.41 requires individual-level genotype and
phenotype data. Thus, SHom and SHet are quite general
and can be applied to a wide range of data and study de-
signs, and they require only that estimates exist for a
given SNP.
In contrast to the subset-based meta-analysis,18 SHom
and SHet do not specifically identify a subset of associated
traits. However, trait-specific meta-analysis results can be
examined after a SNP is identified by SHet, which will
allow one to see whether the association evidence from
SHet is contributed by only a subset of the traits. When
maximizing the statistic in Equation 3, we can record
which trait or cohort contributed to the final statistic.
The current SHom and SHet test CP associations for only
one SNP. Huang et al.24 developed an interesting
method, PRIMe, which can test a pleiotropic effect for
multiple variants in a genomic region. It should not be
difficult to extend SHom and SHet to test for multiplen Genetics 96, 21–36, January 8, 2015 31
Figure 7. QQ Plots and Manhattan Plots after Combining SBP, DBP, and HTN via SHom and SHet for the COGENT BP GWAS Data
Shown are QQ plots (A), Manhattan plot of SHet (B), and Manhattan plot of SHom (C).variants in a genomic region by using a similar idea as
the PRIMe uses, although further studies are warranted
to investigate this.
Our proposed statistics SHom and SHet use the summary
statistics to estimate the correlation coefficients among32 The American Journal of Human Genetics 96, 21–36, January 8, 20traits and cohorts. If trait correlations are known, SHom
and SHet can also be applied by supplying the correlation
matrix in Equation 3 without using genome-wide sum-
mary statistics. There are advantages to using summary sta-
tistics instead of individual-level data. First, as pointed out15
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The Aby Lin and Zeng,42 there is no asymptotic efficiency gain
by analyzing individual-level data compared with meta-
analysis when the parameter of interest has a common
value across studies, although this aspect of performance
is less clear when heterogeneity is present. Second, in prac-
tice it is easier and more feasible to obtain summary statis-
tics than individual-level data. Finally, study-specific anal-
ysis is better to control the confounding within different
study designs by environmental factors and between study
designs by batch effects across experiments than pooling
all data.
In summary, the proposed general statistics SHom and
SHet are useful for detecting CP associations. In partic-
ular, SHet is better for analyzing multiple different phe-
notypes because heterogeneity occurs frequently. These
methods could easily be deployed in existing consortia
collections of association study metadata to improve
the chances of novel discoveries and provide more re-
turn from those investments, as we have demonstrated
in the COGENT consortium. The software of SHom
and SHet can be freely downloaded from the author’s
website.Supplemental Data
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Figure 8. Regional Association Plots
Regional association plots of the four SNPs reaching genome-wide significance (p < 5 3 108) by SHet for the COGENT BP GWAS data.
The most significant SNP at each locus is shown in purple. The fine-scale recombination rate is shown as a blue vertical line. Gene po-
sitions are shown at the bottom.Acknowledgments
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